CN117915907A - 治疗铜代谢相关疾病或障碍的方法 - Google Patents

治疗铜代谢相关疾病或障碍的方法 Download PDF

Info

Publication number
CN117915907A
CN117915907A CN202280061276.3A CN202280061276A CN117915907A CN 117915907 A CN117915907 A CN 117915907A CN 202280061276 A CN202280061276 A CN 202280061276A CN 117915907 A CN117915907 A CN 117915907A
Authority
CN
China
Prior art keywords
weeks
subject
years
copper
tetrathiomolybdate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280061276.3A
Other languages
English (en)
Chinese (zh)
Inventor
尤金·斯科特·斯温森
潘伟坚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CN117915907A publication Critical patent/CN117915907A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90287—Oxidoreductases (1.) oxidising metal ions (1.16)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280061276.3A 2021-09-07 2022-09-06 治疗铜代谢相关疾病或障碍的方法 Pending CN117915907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241441P 2021-09-07 2021-09-07
US63/241,441 2021-09-07
PCT/US2022/042664 WO2023038909A1 (en) 2021-09-07 2022-09-06 Methods of treating copper metabolism-associated diseases or disorders

Publications (1)

Publication Number Publication Date
CN117915907A true CN117915907A (zh) 2024-04-19

Family

ID=85507733

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280061276.3A Pending CN117915907A (zh) 2021-09-07 2022-09-06 治疗铜代谢相关疾病或障碍的方法

Country Status (6)

Country Link
US (1) US20240342127A1 (https=)
EP (1) EP4398896A4 (https=)
JP (1) JP2024534936A (https=)
CN (1) CN117915907A (https=)
CA (1) CA3230084A1 (https=)
WO (1) WO2023038909A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023199A1 (en) * 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147887B2 (en) * 2014-12-17 2021-10-19 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson disease
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3880809A4 (en) * 2018-11-16 2023-01-11 Encoded Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF WILSON'S DISEASE
EP4243806A1 (en) * 2020-11-13 2023-09-20 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2023023199A1 (en) * 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders

Also Published As

Publication number Publication date
US20240342127A1 (en) 2024-10-17
JP2024534936A (ja) 2024-09-26
EP4398896A1 (en) 2024-07-17
WO2023038909A1 (en) 2023-03-16
CA3230084A1 (en) 2023-03-16
EP4398896A4 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
Rogers et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study
Khosravan et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
JP2023075247A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
Groothoff et al. Nedosiran safety and efficacy in PH1: interim analysis of PHYOX3
Wampers et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study
Barcelos et al. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial
Lieske et al. PHYOX3: nedosiran long-term safety and efficacy in patients with primary hyperoxaluria type 1
CN117915907A (zh) 治疗铜代谢相关疾病或障碍的方法
US20250082674A1 (en) Methods of treating copper metabolism-associated diseases or disorders
CA3218914A1 (en) Iptacopan for the treatment of atypical hemolytic uremic syndrome
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
JP2024539949A (ja) ボクセロトールを投与する方法
US20220071938A1 (en) Treatment of hyperammonemia in patients with renal insufficiency
CN114828960A (zh) 治疗儿童个体的cln2病的方法
Lai et al. Clinical Pharmacist Involved in the Treatment of Pneumocystis carinii Pneumonia: A Case Report
US20240122928A1 (en) Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition Disorder
US20250312297A1 (en) Reduction of healthcare resource utilization by patients treated with intranasally-administered metoclopramide
Lin et al. Gender difference in the association of OSBPL8 polymorphisms with nephrolithiasis within a Chinese cohort
US20250375459A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
VX14-661-110 study group Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
CN121263186A (zh) 用厄达替尼治疗局部晚期或转移性尿路上皮癌
CN116685334A (zh) 治疗铜代谢相关疾病或障碍的方法
HK40077860A (en) Methods for treating cln2 disease in pediatric subjects
Merlini et al. GP 2.15 EUROSMART: European Spinal Muscular Atrophy Randomised Placebo-Controlled Trial of acetyl-L-carnitine in spinal muscular atrophy
Kales et al. Psychiatry in the Elderly

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination